Carregant...
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...
Guardat en:
| Publicat a: | ERJ Open Res |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
European Respiratory Society
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6983496/ https://ncbi.nlm.nih.gov/pubmed/32010719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00204-2019 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|